David R. Spigel

3 weeks ago | pharmacytimes.com | Gillian McGovern |David R. Spigel

Pharmacy Times® interviewed David Spigel, MD, medical oncologist,chief scientific officer at Sarah Cannon Research Institute, who discussed a study on patients with early-stage non-small cell lung cancer (NSCLC) to determine the need for chemotherapy, of which the findings were presented as part of the 2025 American Society of Clinical Oncology Annual Meeting.

Jul 3, 2024 | targetedonc.com | David R. Spigel

David Spigel, MD, chief scientific officer at Sarah Cannon Research Institute in Nashville, Tennessee, explains some of the unmet needs for patients with limited-stage small cell lung cancer (SCLC) and how they led to the initiation of the ADRIATIC trial (NCT03703297).

Jun 7, 2024 | onclive.com | David R. Spigel

CommentaryVideoJune 7, 2024Author(s):David R. Spigel, MD, discusses findings from the phase 3 ADRIATIC trial in patients with limited-stage small cell lung cancer. David R. Spigel, MD, chief scientific officer, Sarah Cannon Research Institute, discusses findings from the first planned interim analysis of the phase 3 ADRIATIC trial (NCT03703297) in patients with limited-stage small cell lung cancer (LS-SCLC).

Apr 22, 2024 | ascopubs.org | David R. Spigel |Alejandro Navarro |James Yang

1 SCLC is characterized by a rapid doubling time and early metastases,2 and most patients present with extensive-stage or metastatic disease at diagnosis.3,4 The aggressive nature of SCLC means that affected patients face a poorer prognosis than those with any other type of lung cancer.

Mar 1, 2024 | jitc.bmj.com | Heinz-Josef Lenz |Aparna R. Parikh |David R. Spigel |Allen L. Cohn

DiscussionPhase 2 results from the CheckMate 9X8 trial did not demonstrate a statistically significant improvement in median PFS with nivolumab plus SOC versus SOC in the first-line treatment of patients with mCRC. The PFS curves overlapped before separating at approximately 12 months; nivolumab plus SOC showed numerically higher PFS rates after 12 months compared with SOC. PFS subgroup analyses showed a numerical trend favoring nivolumab plus SOC across multiple subgroups (HR<1).